Document Detail


The pharmacology of esomeprazole and its role in gastric acid related diseases.
MedLine Citation:
PMID:  19606942     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Esomeprazole (S-isomer of omeprazole) demonstrates a better pharmacokinetic/pharmacodynamic profile than the racemic product omeprazole. Esomeprazole's pharmacological activity of gastric acid secretion is through proton pump inhibition. The pharmacokinetic properties provide for an enhanced pharmacological effect. Esomeprazole is rapidly absorbed and the extent of absorption is higher resulting in higher systemic absorption of esomeprazole (bioavailability), which coupled with reduced clearance results in greater systemic exposure. This pharmacodynamic profile then provides for a prolongation of inhibition of gastric acid output and correlates well with its more beneficial therapeutic efficacy over omeprazole and some of the other proton-pump inhibitors. It has been well proven as an effective agent in the treatment of gastro-esophagitis reflux disease, (reflux esophagitis and non-erosive reflux disease), NSAID-induced gastric-intestinal symptoms and ulcers, Helicobacter pylori infection and Zollinger-Ellison syndrome. Esomeprazole has a good tolerability profile and a low potential for drug interaction.
Authors:
Consuelo L Saccar
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  5     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-19     Completed Date:  2009-12-14     Revised Date:  2013-01-07    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1113-24     Citation Subset:  IM    
Affiliation:
Asthma & Allergy Research Associates, Upland, PA 19013, USA. drsaccar@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Drug Interactions
Esomeprazole Sodium
Gastrointestinal Diseases / drug therapy*
Humans
Omeprazole / adverse effects,  pharmacokinetics,  pharmacology*,  therapeutic use*
Chemical
Reg. No./Substance:
73590-58-6/Omeprazole; L2C9GWQ43H/Esomeprazole Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion...
Next Document:  Design and in vitro evaluation of formulations with pH and transit time controlled sigmoidal release...